Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Lymphoma 44Breast Neoplasms 26Sarcoma 19Precursor Cell Lymphoblastic Leukemia-Lymphoma 17Burkitt Lymphoma 14Neuroblastoma 13Hodgkin Disease 13Leukemia 12Lymphoma, Large B-Cell, Diffuse 11Lymphoma, Follicular 8Wilms Tumor 7Sarcoma, Synovial 7Neurofibrosarcoma 7Leiomyosarcoma 7Histiocytoma, Malignant Fibrous 7Hemangiosarcoma 7Fibrosarcoma 7Endometrial Neoplasms 7Urinary Bladder Neoplasms 6Multiple Myeloma 6Malignant mesenchymal tumor 6Liposarcoma 6Rhabdomyosarcoma 5Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 5Lymphoma, Mantle-Cell 5Lymphoma, Large-Cell, Anaplastic 5Kidney Neoplasms 5Hemangiopericytoma, Malignant 5Waldenstrom Macroglobulinemia 4Sarcoma, Alveolar Soft Part 4

Interventions

pegfilgrastim 1Taxes 1Platinum 1Paclitaxel 1Granulocyte Colony-Stimulating Factor 1Fulvestrant 1Filgrastim 1Doxorubicin 1Cisplatin 1Carboplatin 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Recurrent Uterine Corpus Carcinoma × Doxorubicin × Clear all
NCT00063999 2021-10-19

Doxorubicin Hydrochloride, Cisplatin, and Paclitaxel or Carboplatin and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer

GOG Foundation

Phase 3 Completed
1,381 enrolled 12 charts
Gynecologic

Recurrent Uterine Corpus Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡